What Did You Buy Today?

[Rasec]

(02-01-2017, 05:39 PM)EricL Wrote:

(02-01-2017, 05:29 PM)Rasec Wrote: Considering if I should get in UPS. I'm a bit concerned with a potential trade war with China which could impact UPS severely.

Why would a trade war with China impact UPS severely? Isn't most of their business in U.S. and Europe?

The revenue comes from NA, but where is the merchandise coming from?

[DividendGarden]

LB at $58, a 52-week low.

[Binary]

D at 71.61, was also looking at LB, but will wait with that.

[navyasw02]

Bought more CVS. Definitely overweight on it now.

[Rasec]

Ended up buying 30 shares of UPS, let's trust in some common sense from our dear leaders...

[Rasec]

GILD falling 8-9% today, looking ugly. I didn't want to but I may end up buying more and beeing overweight.

[EricL]

(02-08-2017, 09:47 AM)Rasec Wrote: GILD falling 8-9% today, looking ugly. I didn't want to but I may end up buying more and beeing overweight.

Might be worth waiting a few days on GILD, could be prolonged selling as it hits new 52-week lows.

[DividendDragon]

Bought some LSE: ULVR and LSE: RNK

[KTMarty]

Just joined the Mikey Mouse Club

[divmenow]

GILD is done. No growth, nothing in the pipeline. Listen to the conference call. One of the worst ones I ever heard. CEO should be fired. That stock has way more downside left. Nothing more then a bond now.

[EricL]

(02-08-2017, 11:18 AM)divmenow Wrote: GILD is done. No growth, nothing in the pipeline. Listen to the conference call. One of the worst ones I ever heard. CEO should be fired. That stock has way more downside left. Nothing more then a bond now.

I though this was an excellent comment on Seeking Alpha:

Hang in there Bret. Without their HCV franchise, they would have revenues of $15-15.5 billion this year, EPS of around $5.50, and at least mid single digit growth. The DCF value would be in the $80s and the P/E would be around 15. So at $66, the market is giving their HCV business a negative value. Go figure.

Gilead certainly has some issues, but it does have significant cash flows and some good drugs other than the HCV franchise. I agree that share price isn't going anywhere until the declining revenue trend reverses, but I think the rumors of Gilead's demise are a bit premature.

[Rasec]

(02-08-2017, 11:43 AM)EricL Wrote:

(02-08-2017, 11:18 AM)divmenow Wrote: GILD is done. No growth, nothing in the pipeline. Listen to the conference call. One of the worst ones I ever heard. CEO should be fired. That stock has way more downside left. Nothing more then a bond now.

I though this was an excellent comment on Seeking Alpha:

Hang in there Bret. Without their HCV franchise, they would have revenues of $15-15.5 billion this year, EPS of around $5.50, and at least mid single digit growth. The DCF value would be in the $80s and the P/E would be around 15. So at $66, the market is giving their HCV business a negative value. Go figure.

Gilead certainly has some issues, but it does have significant cash flows and some good drugs other than the HCV franchise. I agree that share price isn't going anywhere until the declining revenue trend reverses, but I think the rumors of Gilead's demise are a bit premature.

This comment made me think...

Quote:Your comment is in jest but it has an important nugget of truth.

Yesterday, during the CC, the CEO said something like "we don't have a chronic patient base, so all our revenues come from new patient starts". English Translation: Our drugs are so powerful and useful they cure the sick person. If we had only developed slightly less powerful drugs that needed lifelong purchase, we could keep those "customers" paying us forever - and thus have more predictable revenue streams.

What a perverse profit incentive this gives drug companies - you are better off finding a therapy that people need to keep purchasing as opposed to finding a cure.

What a beleaguered industry this is, where the incentives are so perversely aligned and where you can invent a drug 20 years ago and keep collecting income from that for all that time.

GILD may be my first and last biotech investment.